First-in-Human trial for autoimmune dryness disease halted
NCT ID NCT06544642
Summary
This was the first study to test a new oral drug called ASP5502 in people. The main goal was to check its safety and how the body processes it. It involved healthy adults and people with primary Sjögren's syndrome, an autoimmune disease that causes severe dryness and fatigue. The study was terminated and did not proceed to later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit Inc
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.